Report on a single-topic conference on "Chronic viral hepatitis-strategies to improve effectiveness of screening and treatment"

Hepatology

Volumn 55, Issue 1, 2012, Pages 307-315

  Ward, John W ^a   Lok, Anna S F ^b   Thomas, David L ^c   El Serag, Hashem B ^d   Kim, W Ray ^e  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

^e MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BOCEPREVIR; HEPATITIS B SURFACE ANTIGEN; PEGINTERFERON; RIBAVIRIN; TELAPREVIR;

ANTIVIRAL THERAPY; CHRONIC HEPATITIS; CLINICAL EFFECTIVENESS; CLINICAL TRIAL (TOPIC); COMORBIDITY; CONFERENCE PAPER; DISEASE SURVEILLANCE; DRUG EFFICACY; ETHNICITY; HEALTH CARE ACCESS; HEALTH CARE COST; HEALTH CARE PERSONNEL; HEALTH CARE PLANNING; HEALTH EDUCATION; HEALTH PROGRAM; HEPATITIS B; HEPATITIS C; HOSPITAL POLICY; HUMAN; INTEGRATED HEALTH CARE SYSTEM; LABORATORY TEST; MORBIDITY; MORTALITY; NONBIOLOGICAL MODEL; PATIENT COUNSELING; PATIENT REFERRAL; POPULATION; PREGNANT WOMAN; PRIORITY JOURNAL; PUBLIC-PRIVATE PARTNERSHIP; RISK ASSESSMENT; RURAL HEALTH CARE; TOTAL QUALITY MANAGEMENT; TREATMENT DURATION; UNITED STATES; VACCINATION; VIRUS HEPATITIS; VIRUS LOAD; VIRUS TRANSMISSION;

CHRONIC DISEASE; HEPATITIS, VIRAL, HUMAN; HUMANS; MASS SCREENING; PREVALENCE; VIRAL HEPATITIS VACCINES;

EID: 84155174998     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.24797     Document Type: Conference Paper

References (38)

1. Institute of Medicine. Hepatitis and Liver Cancer: A National Strategy for Prevention and Control of Hepatitis B and C. Washington, DC: National Academies Press; January 11, 2010.
2. Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006; 144: 705-714.
3. Ioannou GN. Hepatitis B virus in the United States: infection, exposure, and immunity rates in a nationally representative survey. Ann Intern Med 2011; 154: 319-328.
4. Museru OI, Vargas M, Kinyua M, Alexander KT, Franco-Paredes C, Oladele A. Hepatitis B virus infection among refugees resettled in the U.S.: high prevalence and challenges in access to health care. J Immigr Minor Health 2010; 12: 823-827.
5. Centers for Disease Control and Prevention. National, state and local area vaccination coverage among children aged 19-35 months-United States, 2009. MMWR Morb Mortal Wkly Rep 2010; 59: 1171-1177.
6. Mast EE, Weinbaum CM, Fiore AE, Alter MJ, Bell BP, Finelli L, et al.; Advisory Committee on Immunization Practices; Centers for Disease Control and Prevention. Comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) Part II: Immunization of Adults. MMWR Recomm Rep 2006; 55: 1-33.
7. Centers for Disease Control and Prevention. Surveillance for Viral Hepatitis - United States, 2009.
8. Kanwal F, Hoang T, Kramer JR, Asch SM, Goetz MB, Zeringue A, et al. Increasing prevalence of HCC and cirrhosis in patients with chronic hepatitis C virus infection. Gastroenterology 2011; 140: 1182-1188.
9. Centers for Disease Control and Prevention. Hepatitis C virus infection among persons 15-24 years. Massachusetts, 2002-2009. MMWR Morb Mortal Wkly Rep 2011; 60: 537-541.
10. Rajendra A, Wong JB. Economics of chronic hepatitis B and hepatitis C. J Hepatol 2007; 47: 608-617.
11. Trust for America's Health/AASLD. HBV & HCV: America's Hidden Epidemics. Washington, DC: Trust for America's Health; 2010.
12. US Department of Health and Human Services. Combating the Silent Epidemic: Action Plan for the Prevention, Care & Treatment of Viral Hepatitis. Washington, DC: Department of Health and Human Services; 2011.
13. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461: 399-401.
14. Poordad F, McCone J Jr, Bacon BR, Bruno S, Manns MP, Sulkowski MS, et al.; SPRINT-2 Investigators. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1195-1206.
15. Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364: 2405-2416.
16. Bailey MB, Shiau R, Zola J, Fernyak SE, Fang T, So SK, et al. San Francisco hep B free: a grassroots community coalition to prevent hepatitis B and liver cancer. J Community Health 2011; 36: 538-551.
17. Institute of Medicine. Crossing the Quality Chasm: A New Health System for the 21st Century. Washington, DC: National Academies Press; March 1, 2001.
18. Centers for Medicare and Medicaid Services. 2010 Physician Quality Reporting Index, Version 4.0. Published November 13, 2009. Accessed November 2011.
19. Shehab TM, Sonnad S, Gebremariam A, Schoenfeld P. Knowledge of hepatitis C screening and management by internal medicine residents: trends over 2 years. Am J Gastroenterol 2002; 97: 1216-1222.
20. Willis BC, Wortley P, Wang SA, Jacques-Carroll L, Zhang F. Gaps in hospital policies and practices to prevent perinatal transmission of hepatitis B virus. Pediatrics 2010; 125: 704-711.
21. Din ES, Wasley A, Jacques-Carroll L, Sirotkin B, Wang S. Estimating the number of births to hepatitis B virus-infected women in 22 states, 2006. Pediatr Infect Dis J 2011; 30: 575-579.
22. Fischer LR, Tope DH, Conboy KS, Hedblom BD, Ronberg E, Shewmake DK, et al. Screening for hepatitis C virus in a health maintenance organization. Arch Intern Med 2000; 160: 1665-1673.
23. Southern WN, Drainoni ML, Smith BD, Christiansen CL, McKee D, Gifford AL, et al. Hepatitis C testing practices and prevalence in a high-risk urban ambulatory care setting. J Viral Hepat 2011; 18: 474-481.
24. Arora S, Kalishman S, Thornton K, Dion D, Murata G, Deming P, et al. Expanding access to hepatitis C virus treatment-Extension for Community Healthcare Outcomes (ECHO) project: disruptive innovation in specialty care. HEPATOLOGY 2010; 52: 1124-1133.
25. Grebely J, Raffa JD, Meagher C, Duncan F, Genoway KA, Khara M, et al. Directly observed therapy for the treatment of hepatitis C virus infection in current and former injection drug users. J Gastroenterol Hepatol 2007; 22: 1519-1525.
26. Litwin AH, Harris KA Jr, Nahvi S, Zamor PJ, Soloway IJ, Tenore PL, et al. Successful treatment of chronic hepatitis C with pegylated interferon in combination with ribavirin in a methadone maintenance treatment program. J Subst Abuse Treat 2009; 37: 32-40.
27. Kanwal F, Hoang T, Spiegel BM, Eisen S, Dominitz JA, Gifford A, et al. Predictors of treatment in patients with chronic hepatitis C infection - role of patient versus nonpatient factors. HEPATOLOGY 2007; 46: 1741-1749.
28. Knott A, Dieperink E, Willenbring ML, Heit S, Durfee JM, Wingert M, et al. Integrated psychiatric/medical care in a chronic hepatitis C clinic: effect on antiviral treatment evaluation and outcomes. Am J Gastroenterol 2006; 101: 2254-2262.
29. Arora S, Thornton K, Murata G, Deming P, Kalishman S, Dion D, et al. Outcomes of treatment for hepatitis C virus infection by primary care providers. N Engl J Med 2011; 364: 2199-2207.
30. Saag MS. Ryan White: an unintentional home builder. AIDS Read 2009; 19: 166-168.
31. Chu C, Selwyn PA. An epidemic in evolution: the need for new models of HIV care in the chronic disease era. J Urban Health 2011; 88: 556-566.
32. Landon BE, Hicks LS, O'Malley AJ, Lieu TA, Keegan T, McNeil BJ, et al. Improving the management of chronic disease at community health centers. N Engl J Med 2007; 356: 921-934.
33. Wagner EH, Davis C, Schaefer J, Von Korff M, Austin B. A survey of leading chronic disease management programs: are they consistent with the literature? Manag Care Q 1999; 7: 56-66.
34. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. HEPATOLOGY 2009; 50: 661-662.
35. Cohen C, Holmberg SD, McMahon BJ, Block JM, Brosgart CL, Gish RG, et al. Is chronic hepatitis B being undertreated in the United States? J Viral Hepat 2011; 18: 377-383.
36. Mehta SH, Genberg BL, Astemborski J, Kavasery R, Kirk GD, Vlahov D, et al. Limited uptake of hepatitis C treatment among injection drug users. J Community Health 2008; 33: 126-133.
37. Kramer JR, Hachem CY, Kanwal F, Mei M, El-Serag HB. Meeting vaccination quality measures for hepatitis A and B virus in patients with chronic hepatitis C infection. HEPATOLOGY 2011; 53: 42-52.
38. Davila JA, Henderson L, Kramer JR, Kanwal F, Richardson PA, Duan Z, et al. Utilization of surveillance for hepatocellular carcinoma among hepatitis C virus-infected veterans in the United States. Ann Intern Med 2011; 154: 85-93.